BPC-157 vs TB-500: Mechanism, Dosage, and Why Researchers Stack Them

If you've spent any time reading recovery peptide research, you've seen BPC-157 and TB-500 mentioned in the same sentence. They're often paired in protocols. They're also fundamentally different molecules with different mechanisms. Here's how they actually compare.

At a glance

	BPC-157	TB-500
Origin	Stomach (synthetic fragment of Body Protective Compound)	Thymosin Beta-4 (synthetic fragment)
Length	15 amino acids	~17 amino acids (active region)
Half-life	~4 hours	~60 hours
Primary mechanism	Angiogenesis, GH receptor upregulation, NO signaling	G-actin sequestration, cell migration
Typical research dose	250–500 mcg, 1–2× daily	2–5 mg, 2× weekly
Strongest evidence	Gut healing, tendon repair, angiogenesis	Tissue regeneration, cardiac repair

Mechanism — same goal, different paths

BPC-157 drives angiogenesis (new blood vessel growth) and modulates the nitric oxide and growth-hormone receptor pathways. It supports wound repair from the vascular side — getting blood, oxygen, and growth signals to damaged tissue.

TB-500 regulates G-actin sequestration — the cytoskeletal protein that drives cell migration, differentiation, and tissue remodeling. It supports repair from the structural side — getting cells where they need to go to rebuild tissue.

This complementarity is why they're stacked: BPC-157 brings the supply lines, TB-500 brings the construction crew.

Dose and frequency

The half-lives are the key difference for protocol design:

• BPC-157 has a ~4-hour half-life. Most research protocols dose it once or twice daily, often locally (near the site of interest). 250–500 mcg per administration.
• TB-500 has a ~60-hour half-life. Most research protocols use a loading phase (2–5 mg twice weekly for 4–6 weeks) followed by a maintenance phase.

This means BPC-157 is in your daily routine; TB-500 is on your calendar.

Evidence base

BPC-157 has been studied for over two decades, primarily by Sikiric and colleagues. The literature includes hundreds of papers covering tendon healing, gut repair, neuroprotection, and angiogenesis — mostly in rodent models. Human evidence is limited.

TB-500's active region maps to Thymosin Beta-4, which has been studied in clinical trials for corneal injuries and cardiac repair (RegeneRx Biopharmaceuticals' development program). The full clinical-grade TB-4 has more human data than the TB-500 fragment specifically.

Side effects

Both are generally well-tolerated in animal studies. Common reports include:

• BPC-157: mild injection-site irritation, transient fatigue, occasional nausea.
• TB-500: lightheadedness shortly after injection, mild lethargy in the first week, injection-site sensitivity.

Long-term human safety data is limited for both.

The "Wolverine Stack"

The combination of BPC-157 + TB-500 is colloquially called the "Wolverine Stack" for its association with rapid recovery research. A representative protocol from the literature:

• BPC-157 250 mcg, 2× daily, subcutaneous, 4 weeks
• TB-500 2.5 mg, 2× weekly, subcutaneous, 4 weeks
• Reassess at 4 weeks; cycle 4 weeks off

Both calculations are easy in the PeptideHub calculator — pick the peptide, enter your vial size, see the units to draw.

Which one should you research first?

If you're new to the recovery peptide literature:

• Start with BPC-157 if your interest is gut, tendon, or local soft-tissue.
• Start with TB-500 if your interest is systemic tissue regeneration or cardiac/longevity endpoints.
• Read both before considering a stack.

Sourcing the stack

Several research-grade vendors carry both peptides individually or pre-bundled with bacteriostatic water and syringes. Before sourcing either compound, read our vendor checklist — third-party HPLC and mass-spec COAs on every batch are the minimum bar.

Next steps

• Read the full BPC-157 page for dosing detail.
• Read the full TB-500 page for protocol notes.
• Use the calculator to plan units for both.